An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer

  • Markman, Ben (Primary Chief Investigator (PCI))
  • Brooks, Christine (Project Manager)

Project: Research

Project Details

Effective start/end date8/12/228/12/24


  • Clinical trial
  • Colorectal Cancer
  • Trastuzumab